Metrohm USA Announces Winner of Young Chemist Award
PTSM: Pharmaceutical Technology Sourcing and Management
Metrohm USA presented the Young Chemist Award to Aldin Malkoc for his work on cooperative, DNA-based molecular elements for electrochemical biosensors.
On Feb. 17, 2017, Metrohm USA announced that Aldin Malkoc is the winner of the company’s 2017 Young Chemist Award. Malkoc is completing his graduate work at Arizona State University where he works under the supervision of professor Michael Caplan, chair of the Biomedical Engineering Department, and assistant professor Jeffrey LaBelle.
Malkoc’s research focuses on cooperative, DNA-based molecular elements for electrochemical biosensors. This rapid, point-of-care, low-cost, and highly specific method of genetic mutation detection is a new technology that has the potential to impact healthcare in developing countries and underrepresented clinics where low-cost and rapid treatment are important.
The Young Chemist Award is open to all undergraduate, graduate, post-graduate, and doctorate students residing and studying in the United States and Canada who are performing novel research in the fields of titration, ion chromatography, spectroscopy, and electrochemistry.
Source: Metrohm USA
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
